NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

Area of Science:

• Hematology
• Oncology
• Radiation Oncology

Background:

• Hodgkin lymphoma (HL) is a rare B-cell malignancy with improving cure rates due to modern therapies.
• Current treatment considerations for HL increasingly emphasize managing long-term toxicities.
• Classical HL (cHL) and nodular lymphocyte-predominant HL are the primary classifications of this lymphoma.

Purpose of the Study:

• To discuss recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Hodgkin lymphoma.
• To highlight key changes concerning radiation therapy dose constraints in HL management.
• To review updated recommendations for treating advanced-stage and relapsed or refractory classical HL.

Main Methods:

• Review of the latest NCCN Guidelines for Hodgkin lymphoma.
• Analysis of updated recommendations on radiation therapy protocols.
• Evaluation of treatment strategies for advanced, relapsed, or refractory classical HL.

Main Results:

• NCCN Guidelines now include specific radiation therapy dose constraints for HL management.
• Updated guidance addresses the complexities of treating advanced-stage classical HL.
• Revised approaches are provided for managing relapsed or refractory classical HL cases.

Conclusions:

• Recent NCCN guideline updates focus on optimizing HL treatment by addressing radiation toxicity and advanced disease management.
• These insights aim to improve patient outcomes by refining therapeutic strategies for classical HL.
• The guidelines provide clinicians with current best practices for Hodgkin lymphoma care.